Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Nov 24;314(20):2137-2146.
doi: 10.1001/jama.2015.15217.

Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial

Writing Committee for the Diabetic Retinopathy Clinical Research Network; Jeffrey G Gross  1 , Adam R Glassman  2 , Lee M Jampol  3 , Seidu Inusah  2 , Lloyd Paul Aiello  4 , Andrew N Antoszyk  5 , Carl W Baker  6 , Brian B Berger  7 , Neil M Bressler  8 , David Browning  5 , Michael J Elman  9 , Frederick L Ferris 3rd  10 , Scott M Friedman  11 , Dennis M Marcus  12 , Michele Melia  2 , Cynthia R Stockdale  3 , Jennifer K Sun  4 , Roy W Beck  2
Affiliations
Randomized Controlled Trial

Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial

Writing Committee for the Diabetic Retinopathy Clinical Research Network et al. JAMA. .

Erratum in

Abstract

Importance: Panretinal photocoagulation (PRP) is the standard treatment for reducing severe visual loss from proliferative diabetic retinopathy. However, PRP can damage the retina, resulting in peripheral vision loss or worsening diabetic macular edema (DME).

Objective: To evaluate the noninferiority of intravitreous ranibizumab compared with PRP for visual acuity outcomes in patients with proliferative diabetic retinopathy.

Design, setting, and participants: Randomized clinical trial conducted at 55 US sites among 305 adults with proliferative diabetic retinopathy enrolled between February and December 2012 (mean age, 52 years; 44% female; 52% white). Both eyes were enrolled for 89 participants (1 eye to each study group), with a total of 394 study eyes. The final 2-year visit was completed in January 2015.

Interventions: Individual eyes were randomly assigned to receive PRP treatment, completed in 1 to 3 visits (n = 203 eyes), or ranibizumab, 0.5 mg, by intravitreous injection at baseline and as frequently as every 4 weeks based on a structured re-treatment protocol (n = 191 eyes). Eyes in both treatment groups could receive ranibizumab for DME.

Main outcomes and measures: The primary outcome was mean visual acuity change at 2 years (5-letter noninferiority margin; intention-to-treat analysis). Secondary outcomes included visual acuity area under the curve, peripheral visual field loss, vitrectomy, DME development, and retinal neovascularization.

Results: Mean visual acuity letter improvement at 2 years was +2.8 in the ranibizumab group vs +0.2 in the PRP group (difference, +2.2; 95% CI, -0.5 to +5.0; P < .001 for noninferiority). The mean treatment group difference in visual acuity area under the curve over 2 years was +4.2 (95% CI, +3.0 to +5.4; P < .001). Mean peripheral visual field sensitivity loss was worse (-23 dB vs -422 dB; difference, 372 dB; 95% CI, 213-531 dB; P < .001), vitrectomy was more frequent (15% vs 4%; difference, 9%; 95% CI, 4%-15%; P < .001), and DME development was more frequent (28% vs 9%; difference, 19%; 95% CI, 10%-28%; P < .001) in the PRP group vs the ranibizumab group, respectively. Eyes without active or regressed neovascularization at 2 years were not significantly different (35% in the ranibizumab group vs 30% in the PRP group; difference, 3%; 95% CI, -7% to 12%; P = .58). One eye in the ranibizumab group developed endophthalmitis. No significant differences between groups in rates of major cardiovascular events were identified.

Conclusions and relevance: Among eyes with proliferative diabetic retinopathy, treatment with ranibizumab resulted in visual acuity that was noninferior to (not worse than) PRP treatment at 2 years. Although longer-term follow-up is needed, ranibizumab may be a reasonable treatment alternative, at least through 2 years, for patients with proliferative diabetic retinopathy.

Trial registration: clinicaltrials.gov Identifier: NCT01489189.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Completion of Follow-up for Study Eyes
*Two-year completed visits include those that occurred between 644 and 812 days (between 92 and 116 weeks). ** Participants are not formally screened prior to obtaining an informed consent ITT = Intention-to-treat
Figure 2
Figure 2
Shown are changes in visual acuity over time for the overall cohort (Panel A), for eyes with baseline DME (Panel B), and for eyes without baseline DME (Panel C). Outlying values were truncated to 3 SD from the mean. Bars represent 95% confidence interval on the mean
Figure 2
Figure 2
Shown are changes in visual acuity over time for the overall cohort (Panel A), for eyes with baseline DME (Panel B), and for eyes without baseline DME (Panel C). Outlying values were truncated to 3 SD from the mean. Bars represent 95% confidence interval on the mean
Figure 2
Figure 2
Shown are changes in visual acuity over time for the overall cohort (Panel A), for eyes with baseline DME (Panel B), and for eyes without baseline DME (Panel C). Outlying values were truncated to 3 SD from the mean. Bars represent 95% confidence interval on the mean
See this image and copyright information in PMC

Comment in

References

    1. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–39. - PubMed
    1. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2005;353:839–41. - PubMed
    1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. 2007 http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed 10-13-09.
    1. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981;88(7):583–600. - PubMed
    1. Silva PS, Cavallerano JD, JK S, et al. Proliferative Diabetic Retinopathy. In: Ryan SJ, editor. Retina. 5th. Elsevier; Philadelphia, PA: 2013.

Publication types

MeSH terms

Associated data